Compass Pathways Published Data From Treatment-Resistant Depression Phase 2 Clinical Trial Of Comp360 Psilocybin Alongside Antidepressants In Nature Journal, Neuropsychopharmacology
Portfolio Pulse from Benzinga Newsdesk
COMPASS Pathways plc (NASDAQ:CMPS) has announced positive data from a phase 2 clinical trial of COMP360 psilocybin in conjunction with daily selective serotonin reuptake inhibitors (SSRIs) for treatment-resistant depression. The data has been published in the peer-reviewed Nature journal, Neuropsychopharmacology.
July 17, 2023 | 8:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Positive results from COMPASS Pathways' phase 2 clinical trial of COMP360 psilocybin could potentially boost investor confidence and the company's stock price.
The positive results from the phase 2 clinical trial indicate that COMPASS Pathways' COMP360 psilocybin could be a viable treatment for resistant depression. This could potentially lead to increased demand for the company's stock as investors anticipate future growth and profitability.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100